ADHD raises death risk by 70 percent but medication may cut it by a quarter

People diagnosed with attention-deficit/hyperactivity disorder face a substantially higher risk of dying prematurely than the general population, yet early evidence suggests that taking ADHD medication may meaningfully reduce that risk. That is the central conclusion of a large new systematic review and meta-analysis led by researchers at University College London and the University of Liverpool, published in JAMA Network Open. The study pooled data from 19 cohort investigations covering close to 16 million participants across three continents, making it one of the most comprehensive syntheses to date on mortality among people with ADHD.

The headline numbers are stark. Across the pooled observational studies, adults and children with an ADHD diagnosis had a 70 percent higher rate of death from any cause than people without the diagnosis. The excess risk was not confined to a single category of death. The rate of death by suicide was 90 percent higher among people with ADHD, the rate of death from injuries, whether intentional or accidental, was 55 percent higher, and the rate of death from natural causes was 27 percent higher. In some of the included studies, participants were followed for more than two decades, allowing the researchers to track mortality patterns across a substantial portion of the life course.

Senior author Professor Joshua Stott of UCL Psychology and Language Sciences said the findings build directly on earlier work from his team. We have previously found that people with ADHD have reduced life expectancies, so here we are adding to our understanding of what drives this very concerning statistic, he said. We found that people with ADHD face an increased risk not only of death by suicide and injury, but also of deaths by natural causes, adding to evidence that health inequalities faced by people with ADHD are broad and wide-ranging.

Stott was careful to stress that the diagnosis itself is not an inevitable path to early death. ADHD is not by definition a life-limiting condition, he said, as the right support and treatment can help people with ADHD to live long and healthy lives. He argued that the results underscore the importance of ensuring that everyone who may have ADHD has access to accurate diagnosis and treatment. While diagnosis rates have risen in recent years, he noted, they may still lag behind actual prevalence, particularly among older adults, precisely the group in which mortality risk may be most pertinent.

What might explain the elevated mortality? The researchers point to a converging set of mechanisms. People with ADHD are more likely to experience mental health problems and face challenges with emotional regulation, impulse control and risk-taking, all of which can elevate the likelihood of fatal outcomes such as suicide or accidental injury. They also experience more societal exclusion, disadvantage and stigma, factors that independently shape health trajectories. Unintentional injury deaths, such as road traffic fatalities, may additionally be linked to differences in attention, a core feature of the condition.

Natural-cause mortality, the 27 percent excess in deaths from physical disease rather than external events, fits a broader picture emerging from the same research group. Previous studies led by the UCL co-authors found that people with ADHD experience higher rates of physical health conditions such as cardiovascular disease, metabolic disorders, diabetes and cancer. Mortality from natural causes may be linked to health risk behaviours such as smoking or alcohol use. People with ADHD may also experience challenges with engagement and access to health care, and with adherence to medical treatment, meaning that even when conditions are treatable, the treatment may not reach the people who need it.

Against that backdrop, the most striking finding of the new analysis is the apparent protective signal associated with medication. Among people with ADHD, those who took ADHD medication appeared to have a 25 percent lower mortality risk than those who did not. First author Lucy Corrigan of the University of Liverpool said the results provide early evidence to suggest that medication may play an important role in supporting the health of people with ADHD, but she was quick to add that this is based on a small number of studies and further research is needed to clarify this link. Medication is just part of the story, she said; many people with ADHD benefit from comprehensive, long-term treatment and support.

Senior author Dr Amber John, also of UCL Psychology and Language Sciences and the University of Liverpool, framed the findings as an argument for equity. Many people with ADHD face challenges throughout their lives, she said, so equitable access to evidence-based assessment and treatment is vital to ensure they can live long, healthy lives. The message from the research team is that the mortality gap is not an intrinsic feature of the condition but a reflection of modifiable risks, from untreated symptoms to barriers in health systems.

The authors themselves urge caution in how strongly the results should be read. There were broad differences between the studies included in their analysis, and while they did generally find that ADHD is linked to higher mortality, the individual studies produced very disparate results as to the magnitude of the effect. The medication finding deserves particular restraint in interpretation, the researchers say, because it was based on only three of the 19 included studies. More fundamentally, because all of the studies in the review were observational, it is not possible to infer causality. It remains possible, for example, that people who receive and adhere to medication differ from those who do not in ways that also influence mortality, such as engagement with health services more broadly.

Even with those caveats, the study adds considerable weight to a growing body of evidence that ADHD is a serious public health issue with consequences measured in years of life. Previous research from the same UCL co-authors estimated an apparent reduction in life expectancy for men with diagnosed ADHD of between 4.5 and 9 years, and between 6.5 and 11 years for women. Separate UCL work has suggested that ADHD may be underdiagnosed in adults across England, and that childhood ADHD is linked to midlife physical health problems. Taken together, the picture is of a condition whose long-term health impact has been systematically underestimated, and whose treatment, if the early medication signal holds up in further research, could offer one of the clearest available levers for reducing that impact.

Subject of Research: Mortality risk and medication effects in ADHD

Article Title: ADHD linked to higher mortality but medication may help

Article References: ADHD linked to higher mortality but medication may help. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: ADHD, mortality, meta-analysis, medication, suicide risk, injury deaths, natural-cause mortality, JAMA Network Open, UCL, University of Liverpool, mental health, life expectancy